Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax (NVAX) closed the most recent trading day at $7.64, moving -2.55% from the previous trading session. This move lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow experienced a drop ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...

Novavax's sales for 2023 declined substantially compared to 2022. For the full fiscal year, the company expects total revenue of between $900 million and $1.1 billion.

Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax Inc. closed 60.86% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax has reached a settlement with Gavi, the Vaccine Alliance (Gavi), ending arbitration tied to a 2021 advance purchase agreement (APA) around its prototype COVID-19 vaccine NVX-CoV2373.

Novavax’s recent application for licensing its Covid-19 vaccine in Australia, Canada, and the UK hasn’t gained much traction in the US media. This is odd, given that the vaccine could not only ...